Literature DB >> 22897869

Evaluation of silent thrombus after the Fontan operation.

Jasmine Grewal1, Mosaad Al Hussein, Jaimee Feldstein, Marla Kiess, Jennifer Ellis, Derek Human, Jonathon Leipsic.   

Abstract

BACKGROUND: Thromboembolic complications have been noted after the Fontan operation. However, the prevalence of silent events among an adult contemporary population is not known. Noninvasive screening by any method including computed tomography (CT) has been technically limited to date.
OBJECTIVES: The objective of this study was to evaluate a novel dual-energy CT (DECT) protocol in determining the prevalence of "silent" intracardiac thrombus and thrombus in the Fontan and pulmonary circulations among adults after the Fontan operation.
METHODS: All post-Fontan patients attending the Pacific Adult Congenital Heart Clinic were approached for study participation. Those agreeable underwent a full clinical assessment, cardiopulmonary stress testing, transthoracic echocardiogram, and DECT low kilovoltage imaging protocol.
RESULTS: Twenty-three patients were included in the study (30 ± 10 years, 26% women). Three (13%) patients had evidence of silent thrombi detected on DECT. All three of these patients had an extracardiac conduit and mural thrombus was found within the conduit. Older age at the time of the Fontan operation was associated with the presence of thrombus (21 ± 14 vs. 11 ± 6 years, P =.05).
CONCLUSIONS: Thirteen percent of adult patients post-Fontan procedure have clinically silent thrombi. These were all found among patients with an extracardiac conduit traditionally thought to be at low risk for thromboembolism. Given the significant risk of thromboembolic complications, large randomized prospective studies looking at anticoagulation therapy in all Fontan patients are urgently needed. In the meanwhile, given the important rate of silent thrombi, a systematic robust screening protocol that includes noninvasive low radiation methods such as DECT methods should be considered.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22897869     DOI: 10.1111/j.1747-0803.2012.00699.x

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  6 in total

Review 1.  Thromboembolic complications in adult congenital heart disease: the knowns and the unknowns.

Authors:  Magalie Ladouceur; Clément Karsenty; Victor Waldmann; Barbara Mulder; Sébastien Hascoet
Journal:  Clin Res Cardiol       Date:  2020-10-09       Impact factor: 5.460

2.  Cardiac imaging in adults with congenital heart disease: unknowns and issues related to diagnosis.

Authors:  Cylen Javidan-Nejad; Anderanik Tomasian; Elham Najafpour
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-10

Review 3.  Choosing Between MRI and CT Imaging in the Adult with Congenital Heart Disease.

Authors:  Crystal Bonnichsen; Naser Ammash
Journal:  Curr Cardiol Rep       Date:  2016-05       Impact factor: 2.931

4.  Ablation of Arrhythmias in Patients with Adult Congenital Heart Disease.

Authors:  Rodrigo Gallardo Lobo; Michael Griffith; Joseph De Bono
Journal:  Arrhythm Electrophysiol Rev       Date:  2014-05-18

5.  Comparative trial of the use of antiplatelet and oral anticoagulant in thrombosis prophylaxis in patients undergoing total cavopulmonary operation with extracardiac conduit: echocardiographic, tomographic, scintigraphic, clinical and laboratory analysis.

Authors:  Cristiane Felix Ximenes Pessotti; Marcelo Biscegli Jatene; Ieda Biscegli Jatene; Patrícia Marques Oliveira; Fabiana Moreira Passos Succi; Valeria de Melo Moreira; Rafael Willain Lopes; Simone Rolim Fernandes Fontes Pedra
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Oct-Dec

Review 6.  User-Friendly Vendor-Specific Guideline for Pediatric Cardiothoracic Computed Tomography Provided by the Asian Society of Cardiovascular Imaging Congenital Heart Disease Study Group: Part 1. Imaging Techniques.

Authors:  Sun Hwa Hong; Hyun Woo Goo; Eriko Maeda; Ki Seok Choo; I Chen Tsai
Journal:  Korean J Radiol       Date:  2019-02       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.